1 3

FGF R4 Fc Chimera Protein, Human

FGF R4 Fc Chimera Protein, Human

Catalog Number: UA011375 Brand: UA BIOSCIENCE
Share:
Price:
$300 USD
$300 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Species Human
Synonyms FGFR-4,CD334,Fibroblast growth factor receptor 4
Accession P22455
Amino Acid Sequence

Leu22-Asp369 with hIgG1 Fc Tag at the C-Terminus
Expression System HEK293
Molecular Weight

70-95kDa (Reducing)
Purity ＞95% by SDS-PAGE&HPLC
Conjugation Unconjugated
Tag Human IgG1 Fc
Physical Appearance Lyophilized powder
Storage Buffer

PBS, pH7.4, 5% trehalose
Reconstitution

Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Stability & Storage

· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
Reference

1.Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, Bifulco N, Kim JL, Hodous B, Brooijmans N, Shutes A, Winter C, Lengauer C, Kohl NE, Guzi T. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. Cancer Discov. 2015 Apr;5(4):424-37. 
2.Gao L, Wang X, Tang Y, Huang S, Hu CA, Teng Y. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J Exp Clin Cancer Res. 2017 Jan 9;36(1):8. 
Weiss A, Adler F, Buhles A, Stamm C, Fairhurst RA, Kiffe M, Sterker D, 3.Centeleghe M, Wartmann M, Kinyamu-Akunda J, Schadt HS, Couttet P, Wolf A, Wang Y, Barzaghi-Rinaudo P, Murakami M, Kauffmann A, Knoepfel T, Buschmann N, Leblanc C, Mah R, Furet P, Blank J, Hofmann F, Sellers WR, Graus Porta D. FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer. Mol Cancer Ther. 2019 Dec;18(12):2194-2206.

Background

FGFR4 (fibroblast growth factor receptor 4) is a receptor tyrosine kinase belonging to the FGFR family, whose protein structure consists of an extracellular ligand-binding domain, a single transmembrane helix, and an intracellular kinase domain, functioning as a monomer in complex with the transmembrane protein β-Klotho. This receptor specifically binds endocrine ligands FGF19/FGF21 and regulates bile acid metabolism, liver regeneration, and glucose homeostasis through activating MAPK, PI3K/AKT, and other signaling pathways. In oncology, aberrant FGFR4 activation resulting from FGF19 gene amplification or overexpression serves as a crucial driver of hepatocellular carcinoma (HCC), promoting tumor cell proliferation, invasion, and sorafenib resistance. Clinically, FGFR4 has emerged as a pivotal therapeutic target for precision treatment of HCC, with the first highly selective inhibitors such as BLU-554 (fisogatinib) and FGF401 advancing into clinical trials, offering novel targeted therapeutic strategies for patients with FGF19/FGFR4 pathway-driven cancers, while FGFR4 expression levels are also being explored as predictive biomarkers for treatment efficacy.

Picture

SDS-PAGE

2μg (R: reducing condition, N:non-reducing condition).

SEC-HPLC

The purity of FGF R4 Fc Chimera Protein, Human is more than 95% determined by SEC-HPLC.

SPR

FGF R4 Fc Chimera Protein, Human (Cat. No. UA011375) immobilized on CM5 Chip can bind FGF-4 Protein, Human (Cat. No. UA040046) with an affinity constant of 19.92nM as determined in a SPR assay.